These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 9689395)

  • 1. [Incidence of disposition for malignant hyperthermia in patients with neuromuscular diseases].
    Wappler F; Scholz J; von Richthofen V; Fiege M; Köchling A; Matschke J; Winkler G; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Jun; 33(6):373-80. PubMed ID: 9689395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests].
    Mortier W; Breucking E
    Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [4-chloro-m-cresol-induced contractures of skeletal muscle specimen from patients at risk for malignant hyperthermia].
    Wappler F; Scholz J; von Richthofen V; Fiege M; Steinfath M; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Sep; 32(9):541-8. PubMed ID: 9417254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnosis of susceptibility to malignant hyperthermia with an in vitro contracture test with the phosphodiesterase iii inhibitor enoximone].
    Fiege M; Wappler F; Scholz J; von Richthofen V; Brinken B; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Sep; 33(9):557-63. PubMed ID: 9787864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of malignant hyperthermia episodes with the Clinical Grading Scale].
    von Richthofen V; Wappler F; Scholz J; Fiege M; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Apr; 33(4):244-9. PubMed ID: 9617423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In-vitro-effects of cocaine in skeletal muscle specimens of patients susceptible to malignant hyperthermia].
    Weisshorn R; Wappler F; Fiege M; Gerbershagen M; Schulte Am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2002 Mar; 37(3):138-43. PubMed ID: 11889614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ryanodine contracture threshold times for diagnosis of malignant hyperthermia susceptibility: an experimental approach from a single laboratory.
    Weisshorn R; Wappler F; Fiege M; Gerbershagen MU; Kolodzie K; Alberts P; Horn EP; Schulte Am Esch J
    J Clin Anesth; 2004 Aug; 16(5):353-7. PubMed ID: 15374556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Are morphologic changes in skeletal muscles of patients with malignant hyperthermia diagnostically useful?].
    Anetseder M; Pohl F; Klein R; Müller R; Hoyer A; Horbaschek H; Roggendorf W; Hartung E; Roewer N
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 Oct; 34(10):626-33. PubMed ID: 10548959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis of disposition for malignant hyperthermia--an updated review based on 1,001 studies].
    Olthoff D; Deutrich C; Meinecke CD
    Anaesthesiol Reanim; 1997; 22(2):32-40. PubMed ID: 9235003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The risk of malignant hyperthermia in children undergoing muscle biopsy for suspected neuromuscular disorder.
    Flick RP; Gleich SJ; Herr MM; Wedel DJ
    Paediatr Anaesth; 2007 Jan; 17(1):22-7. PubMed ID: 17184427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
    Ording H; Bendixen D
    Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Is a presymptomatic malignant hyperthermia in-vitro diagnosis with 4-chloro-3-ethyl phenol possible? A study using porcine skeletal preparations].
    Gerbershagen MU; Wappler F; Fiege M; Weisshorn R; Kolodzie K; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2004 Feb; 39(2):81-6. PubMed ID: 14767797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization.
    Guis S; Figarella-Branger D; Monnier N; Bendahan D; Kozak-Ribbens G; Mattei JP; Lunardi J; Cozzone PJ; Pellissier JF
    Arch Neurol; 2004 Jan; 61(1):106-13. PubMed ID: 14732627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met.
    Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R
    Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.
    Ording H; Brancadoro V; Cozzolino S; Ellis FR; Glauber V; Gonano EF; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Kozak-Ribbens G; Kress H; Krivosic-Horber R; Lehmann-Horn F; Mortier W; Nivoche Y; Ranklev-Twetman E; Sigurdsson S; Snoeck M; Stieglitz P; Tegazzin V; Urwyler A; Wappler F
    Acta Anaesthesiol Scand; 1997 Sep; 41(8):955-66. PubMed ID: 9311391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnosis of susceptibility to malignant hyperthermia using the in vitro contracture test].
    Klein W; Spiess-Kiefer C; Küther G; Pongratz D; Lehmann-Horn F
    Anaesthesist; 1987 Dec; 36(12):685-91. PubMed ID: 2830805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histomorphologic examination of skeletal muscle preparations does not differentiate between malignant hyperthermia-susceptible and -normal patients.
    von Breunig F; Wappler F; Hagel C; von Richthofen V; Fiege M; Weisshorn R; Stavrou D; Schulte am Esch J
    Anesthesiology; 2004 Apr; 100(4):789-94. PubMed ID: 15087612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current aspects of the diagnosis of malignant hyperthermia].
    Rüffert H; Olthoff D; Deutrich C; Froster UG
    Anaesthesist; 2002 Nov; 51(11):904-13. PubMed ID: 12434264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inositol 1,4,5-trisphosphate in blood and skeletal muscle in human malignant hyperthermia.
    Wappler F; Scholz J; Köchling A; Steinfath M; Krause T; Schulte am Esch J
    Br J Anaesth; 1997 May; 78(5):541-7. PubMed ID: 9175969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant hyperthermia and central core disease causative mutations in Swedish patients.
    Broman M; Islander G; Müller CR; Ranklev-Twetman E
    Acta Anaesthesiol Scand; 2007 Jan; 51(1):50-3. PubMed ID: 17081152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.